Overview

An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

Status:
Active, not recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

This study is a multi-center, open-label study of intravenous (IV) ANX005 in subjects with, or at risk for, manifest Huntington's Disease (HD).

Phase:

Phase 2

Details

Lead Sponsor:

Annexon, Inc.